QMS Hub
chevron left
FDA Observations Complaint Management

FDA Observations Complaint Management

September 30, 2024
8
 mins read

1. Inadequate Complaint Handling Procedures

Root Cause:
Lack of comprehensive procedures, insufficient training, inadequate trend analysis, failure to escalate complaints, and unclear third-party call center guidance.

Corrective Action:
Revise SOPs, implement robust training, enhance trend analysis, investigate recurring complaints, and provide guidelines for third-party call centers.

Preventive Action:
Establish continuous improvement, robust training, advanced analytical tools, maintain quality dashboard, and hold regular review meetings with third-party providers.

Reference FDA 483:
Company Name: Sun Pharmaceutical Industries Limited
Issue Date: 15-Dec-23
Inspection Dates: 04 Dec 2023 to 15 Dec 2023
Investigators: Pratik S Upadhyay

2. Inadequate Investigation of Unexplained Discrepancies

Root Cause:
Lack of microbial contamination assessment procedures, insufficient training, and unclear escalation criteria for complaint investigations.

Corrective Action:
Revise procedures for microbial assessment, train staff on new procedures, and introduce Quality Control review for microbial-related complaints.

Preventive Action:
Conduct routine audits, enhance complaint intake for microbial indicators, and periodically review microbial assessment criteria based on standards and guidance.

Reference FDA 483:
Company Name: Kilitch Healthcare India Limited
Issue Date: 20-Oct-23
Inspection Dates: 12 Oct 2023 to 20 Oct 2023
Investigators: Anastasia M Shields, Justin A Boyd

3. Deficient Complaint Procedures Impact Drug Safety Evaluation

Root Cause:
Lack of thorough complaint procedures, inefficient product testing, and insufficient employee training.

Corrective Action:
Revise complaint procedures, implement product testing, and train employees on updated procedures.

Preventive Action:
Periodically review complaint procedures, conduct regular training, and implement a tracking system for complaints and investigations.

Reference FDA 483:
Company Name: SCA Pharmaceuticals, LLC
Issue Date: 20-Oct-23
Inspection Dates: 18 Sep 2023 to 20 Oct 2023
Investigators: Jonah S Ufferfilge, John P Mistler

4. Missing Conclusions and Follow-Up in Discrepancy Records

Root Cause:
Unclear investigation procedures, insufficient training, inadequate documentation, and failure to extend investigations to impacted batches and critical processes.

Corrective Action:
Develop comprehensive SOPs, conduct thorough training, enhance record-keeping, and expand investigation scope to include impacted batches and equipment.

Preventive Action:
Regular training programs, periodic review by senior quality personnel, implement digital tracking, and adopt a risk-based approach for investigations.

Reference FDA 483:
Company Name: Sichuan Deebio Pharmaceutical Co. Ltd.
Issue Date: 08-Sep-23
Inspection Dates: 04 Sep 2023 to 08 Sep 2023
Investigators: Arsen Karapetyan, Anders W Evenson

5. Unreviewed Discrepancies and Batch Specification Issues

Root Cause:
Superficial investigations, lack of trained personnel, inadequate QMS, poor risk evaluation, delayed complaint responses, and insufficient environmental control.

Corrective Action:
Strengthen investigation procedures, review QMS, enhance training, implement escalation processes, expedite complaint handling, and upgrade environmental controls.

Preventive Action:
Ensure CAPA effectiveness, regular staff training, update SOPs, integrate risk management, and promote a culture of transparency in reporting quality issues.

Reference FDA 483:
Company Name: Central Admixture Pharmacy Services Inc
Issue Date: 25-Aug-23
Inspection Dates: 10 Jul 2023 to 25 Aug 2023
Investigators: Jolanna A Norton, Rachel C Stanton, Doan N Singh, Xiaohui Shen

6. Missing Investigation Findings and Follow-Up in Records

Root Cause:
No standardized complaint investigation procedure, insufficient training, inadequate quality oversight, lack of trend analysis tools, and ineffective inter-departmental communication.

Corrective Action:
Revise SOPs for complaint handling, implement targeted training, establish quality oversight mechanisms, and enhance trend analysis technology.

Preventive Action:
Institute continuous training, upgrade IT systems for trend analysis, strengthen inter-departmental communication, and regularly review documentation processes in CAPA system.

Reference FDA 483:
Company Name: Novo Nordisk A/S
Issue Date: 04-May-23
Inspection Dates: 27 Apr 2023 to 04 May 2023
Investigators: Prabhu P Raju, Unnee Ranjan, Mikhail Ovanesov, Sergey Akimov

7. Inadequate Procedures for Managing Drug Complaints

Root Cause:
Undefined complaint handling procedures, lack of training, inadequate quality control oversight, and inefficient complaint tracking system.

Corrective Action:
Revise and document complaint procedures, implement comprehensive training, enhance quality control oversight, and upgrade the complaint tracking system.

Preventive Action:
Establish regular audits, periodically review complaint processes, implement feedback loops, and conduct regular training refreshers for staff.

Reference FDA 483:
Company Name: Cipla Limited
Issue Date: 17-Feb-23
Inspection Dates: 06 Feb 2023 to 17 Feb 2023
Investigators: Saleem A Akhtar, Jose E Melendez

LEUCINE 10X QMS
Experience seamless Cleaning Validation
Automate your cleaning validation calculations to reduce errors, achieve compliance, and validate with confidence.
LEUCINE 10X QMS
Experience the Future of Pharma
Integrate your entire shop floor in digital environment, uncover powerful insights and increase productivity.
LEUCINE 10X QMS
Resolve Market Complaints Faster
With automated triage & global regulatory compliance, we ensure swift accurate handling of market complaints.
LEUCINE 10X QMS
Streamline Change Control with AI-Driven Efficiency
Accelerate change implementations while ensuring compliance, thus releasing products faster to market
FDA TRACKER
Free FDA Form 483 Analytics Tool
Mitigate compliance risks in your pharma processes with our large repository of in-depth insights
QMS Hub
chevron left
FDA Observations Complaint Management

FDA Observations Complaint Management

Be Audit-Ready with Our Comprehensive 40+ Point Checklist that covers key areas auditors typically focus on during a pharmaceutical industry audit.

Use it to identify gaps, implement corrective measures, and fortify your CAPA process to ensure compliance and continuous improvement in pharmaceutical operations.

Please enter a business email.
Thank you! Your submission has been received!
Download PDF
Oops! Something went wrong while submitting the form.

Dive Deep into the Following Critical Aspects

Documentation

Ensure all records are complete, accurate, and easily accessible.

Process and System Review

Evaluate the efficiency and effectiveness of your processes and systems.

Regulatory Compliance

Verify adherence to all relevant regulations and standards.

Facility & Personnel

Assess the condition of your facilities and the competence of your staff.

Communication and Coordination

Check the effectiveness of internal and external communication channels.

Follow-up and Monitoring

Ensure ongoing tracking and resolution of CAPAs to maintain compliance.

Ready to Get Started?

300+ pharma facilities globally use Leucine to stay compliant. Speak with one of the expert consultants at Leucine to know how.

Schedule Demo